Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 3/20 | 0.46 |
| ▸ | CA2 | P00918 | 3/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1598773 | 0.85 | RAB9A (0.49) | RAB9ANPC1L3MBTL1LMNAMAPT | |
| SCHEMBL15317893 | 0.78 | CA12 (0.55) | RAB9ANPC1L3MBTL1CA1CA2 | |
| SCHEMBL9972673 | 0.78 | CA12 (0.49) | RAB9ANPC1L3MBTL1CA1CA2 | |
| SCHEMBL6406957 | 0.78 | CA12 (0.61) | RAB9ANPC1L3MBTL1CA1CA2 | |
| SCHEMBL1838503 | 0.75 | ALDH1A1 (0.53) | RAB9ANPC1L3MBTL1PTPN1ALDH1A1 | |
| SCHEMBL2026895 | 0.75 | PPARG (0.48) | RAB9ANPC1L3MBTL1MAPTALDH1A1 | |
| SCHEMBL1834302 | 0.74 | PTPN1 (0.58) | RAB9ANPC1L3MBTL1LMNAMAPT | |
| SCHEMBL1947879 | 0.73 | ALDH1A1 (0.65) | RAB9ANPC1L3MBTL1CA1CA2 | |
| SCHEMBL11100708 | 0.73 | CA12 (0.63) | RAB9ANPC1L3MBTL1CA1CA2 | |
| SCHEMBL2028289 | 0.73 | LMNA (0.50) | RAB9ANPC1LMNAMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226084-A9 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | TECHFIELDS PHARMA CO., LTD. (CN) | 2024-07-11 | — | — | US | disclosed |
| US-11857545-B2 | High penetration prodrug compositions and pharmaceutical composition thereof for treatment of pulmonary conditions | TECHFIELDS PHARMA CO., LTD. (CN) | 2024-01-02 | — | — | US | disclosed |
| US-11813256-B2 | High penetration prodrug compositions and pharmaceutical compositon thereof for treatment of pulmonary conditions | PREMIER RESEARCH INTERNATIONAL, LLC | 2023-11-14 | — | — | US | disclosed |
| US-20230130980-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS OF ANTIMICROBIALS AND ANTIMICROBIAL-RELATED COMPOUNDS | TECHFIELDS PHARMA CO., LTD. (CN) | 2023-04-27 | — | — | US | disclosed |
| US-20180222921-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS OF ANTIMICROBIALS AND ANTIMICROBIAL-RELATED COMPOUNDS | PREMIER RESEARCH INTERNATIONAL, LLC | 2018-08-09 | — | — | US | disclosed |
| US-9969751-B2 | High penetration prodrug compositions of antimicrobials and antimicrobial-related compounds | TECHFIELDS PHARMA CO., LTD. (CN) | 2018-05-15 | — | — | US | disclosed |
| US-20150072961-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | PREMIER RESEARCH INTERNATIONAL, LLC | 2015-03-12 | — | — | US | disclosed |
| US-20130018029-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS OF ANTIMICROBIALS AND ANTIMICROBIAL-RELATED COMPOUNDS | TECHFIELDS PHARMA CO., LTD (CN) | 2013-01-17 | — | — | US | disclosed |
| US-20120157371-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS OF ANTIMICROBIALS AND ANTIMICROBIAL-RELATED COMPOUNDS | PREMIER RESEARCH INTERNATIONAL, LLC | 2012-06-21 | — | — | US | disclosed |
| US-20100040548-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS OF ANTIMICROBIALS AND ANTIMICROBIAL-RELATED COMPOUNDS | TECHFIELDS PHARMA CO., LTD (CN) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226084-A9 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | HRH4, HCAR2, PAH | RAB9A 1734/4885NPC1 480/4885L3MBTL1 4827/4885 |
| US-11813256-B2 | High penetration prodrug compositions and pharmaceutical compositon thereof for treatment of pulmonary conditions | CPA3, PAH, HCAR2 | RAB9A 3565/4885NPC1 1478/4885L3MBTL1 4421/4885 |
| US-20180222921-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS OF ANTIMICROBIALS AND ANTIMICROBIAL-RELATED COMPOUNDS | SLC7A1, VIP, HPGDS | RAB9A 1255/4885NPC1 112/4885L3MBTL1 4793/4885 |
| US-20150072961-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | HRH4, HCAR2, PAH | RAB9A 1734/4885NPC1 480/4885L3MBTL1 4827/4885 |
| US-20230130980-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS OF ANTIMICROBIALS AND ANTIMICROBIAL-RELATED COMPOUNDS | SLC7A1, VIP, HPGDS | RAB9A 1255/4885NPC1 112/4885L3MBTL1 4793/4885 |
| US-20130018029-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS OF ANTIMICROBIALS AND ANTIMICROBIAL-RELATED COMPOUNDS | SLC7A1, VIP, HAMP | RAB9A 1450/4885NPC1 96/4885L3MBTL1 4797/4885 |
| US-20100040548-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS OF ANTIMICROBIALS AND ANTIMICROBIAL-RELATED COMPOUNDS | SLC7A1, VIP, HAMP | RAB9A 1450/4885NPC1 96/4885L3MBTL1 4797/4885 |
| US-11857545-B2 | High penetration prodrug compositions and pharmaceutical composition thereof for treatment of pulmonary conditions | HRH4, HCAR2, PAH | RAB9A 1734/4885NPC1 480/4885L3MBTL1 4827/4885 |
| US-20120157371-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS OF ANTIMICROBIALS AND ANTIMICROBIAL-RELATED COMPOUNDS | SLC7A1, VIP, HPGDS | RAB9A 1255/4885NPC1 112/4885L3MBTL1 4793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.